Enso now handles every real-world asset (RWA) transaction within the ether.fi app, including routing, minting, cross-chain transfers, and liquidity sourcing for over 100 tokenized assets. This integration removes manual bridging challenges, making it seamless for users to buy tokenized equities or mint real-world asset positions. Ether.fi has expanded beyond liquid staking to offer tokenized stocks, metals trading, a crypto-linked spending card with over 110,000 active users, and portfolio-backed loans at around 4% interest. This partnership positions ether.fi as a comprehensive platform for holding, borrowing against, and spending tokenized real-world assets.
The story about Enso handling all RWA execution for the ether.fi app is presented here with Pluang's market data as context. For readers following the broader cryptocurrency market, as of Sep 25, 2026 01:32 WIB, 43 out of 50 major cryptocurrencies on Pluang rose today. Litecoin (LTC) gained 19.51% with a typical hold time of 78 days, contrasting with Harmony (ONE), which fell 16.93% and has a much longer typical hold time of 152 days. Ethereum Classic (ETC) also rose 14.24% but sees a shorter typical hold time of 67 days.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
